COMPLETE LISTING OF ALL CLAIMS, WITH MARKINGS AND STATUS IDENTIFIERS
(Currently amended claims showing deletions ~~by strikethrough~~ and additions by underlining)

1 (canceled): A method of decreasing body weight in a patient, said method comprising administering a therapeutically effective amount of somatostatin or a somatostatin agonist to said patient.

2 (canceled): A method of claim 1, wherein said method comprises administering a therapeutically effective amount of a somatostatin agonist to said patient.

3 (currently amended): A method of ~~claim 2~~ decreasing body weight in a patient, ~~wherein~~ said method comprising administering a therapeutically effective amount of a somatostatin ~~agonist is a somatostatin~~ type-2 receptor agonist to said patient.

4 (canceled): A method of claim 2, wherein said somatostatin agonist is a somatostatin type-5 receptor agonist.

5 (currently amended): ~~A~~ The method of claim 3, wherein said somatostatin type-2 receptor agonist has a Ki of less than 2 nM for the somatostatin type-2 receptor.

6 (canceled): A method of claim 4, wherein said somatostatin type-5 receptor agonist has a Ki of less than 2 nM for the somatostatin type-5 receptor.

7 (currently amended): ~~A~~ The method of claim ~~2~~ 3, wherein said somatostatin agonist is a somatostatin type-2 receptor selective agonist.

8 (canceled): A method of claim 2, wherein said somatostatin agonist is a somatostatin type-5 receptor selective

agonist.

9 (currently amended): ~~A~~ The method of claim 7, wherein said somatostatin type-2 receptor selective agonist has a Ki for the somatostatin type-2 receptor that is at least 10 times less than the Ki for the somatostatin type-1, type-3, type-4, and type-5 receptors.

10 (canceled): A method of claim 8, wherein said somatostatin type-5 receptor selective agonist has a Ki for the somatostatin type-5 receptor that is at least 10 times less than the Ki for the somatostatin type-1, type-2, type-3, and type-4 receptors.

11 (canceled): A method of decreasing body weight in a patient, said method comprising administering a therapeutically effective amount of H-Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys-NH_2, wherein a disulfide bond exists between the free thiols of two Cys residues.

12 (canceled): A method of claim 1, wherein said patient is a non-insulin-dependent diabetic human.

13 (canceled): A method of claim 2, wherein said patient is a non-insulin-dependent diabetic human.

14 (currently amended): ~~A~~ The method of claim 3, wherein said patient is a non-insulin-dependent diabetic human.

15 (canceled): A method of claim 4, wherein said patient is a non-insulin-dependent diabetic human.

16 (currently amended): ~~A~~ The method of claim 5, wherein said patient is a non-insulin-dependent diabetic human.

17 (canceled): A method of claim 6, wherein said patient is a non-insulin-dependent diabetic human.

18 (currently amended): ~~A~~ The method of claim 7, wherein said patient is a non-insulin-dependent diabetic human.

19 (canceled): A method of claim 8, wherein said patient is a non-insulin-dependent diabetic human.

20 (currently amended): ~~A~~ The method of claim 9, wherein said patient is a non-insulin-dependent diabetic human.

21 (canceled): A method of claim 10, wherein said patient is a non-insulin-dependent diabetic human.

22 (canceled): A method of claim 11, wherein said patient is a non-insulin-dependent diabetic human.

23 (currently amended): ~~A~~ The method according to claim ~~1~~ 3 wherein the somatostatin agonist is
H-D-ß-Nal-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH_2,
H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-ß-Nal-NH_2,
H-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-ß-Nal-NH_2,
H-D-ß-Nal-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH_2,
H-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH_2,
H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Pen-Thr-NH_2,
H-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-OH,
H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Pen-Thr-OH,
H-Gly-Pen-Phe-D-Trp-Lys-Thr-Cys-Thr-OH,
H-Phe-Pen-Tyr-D-Trp-Lys-Thr-Cys-Thr-OH,
H-Phe-Pen-Phe-D-Trp-Lys-Thr-Pen-Thr-OH,
H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-ol
H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH_2,
H-D-Trp-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH_2,
H-D-Trp-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH_2,

H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH_2,

H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH_2,

H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH_2,

Ac-D-Phe-Lys*-Tyr-D-Trp-Lys-Val-Asp-Thr-NH_2 (an amide bridge formed between Lys* and Asp),

Ac-hArg(Et)$_2$-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH_2,

Ac-D-hArg(Et)$_2$-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH_2,

Ac-D-hArg(Bu)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH_2,

Ac-D-hArg(Et)$_2$-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH_2,

Ac-L-hArg(Et)$_2$-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH_2,

Ac-D-hArg(CH_2CF_3)$_2$-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH_2,

Ac-D-hArg(CH_2CF_3)$_2$-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH_2,

Ac-D-hArg(CH_2CF_3)$_2$-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Phe-NH_2,

Ac-D-hArg(CH_2CF_3)$_2$-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NHEt,

Ac-L-hArg(CH_2-CF_3)$_2$-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH_2,

Ac-D-hArg(CH_2CF_3)$_2$-Gly-Cys-Phe-D-Trp-Lys(Me)-Thr-Cys-Thr-NH_2,

Ac-D-hArg(CH_2CF_3)$_2$-Gly-Cys-Phe-D-Trp-Lys(Me)-Thr-Cys-Thr-NHEt,

Ac-hArg(CH_3, hexyl)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH_2,

H-hArg(hexyl$_2$)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH_2,

Ac-D-hArg(Et)$_2$-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NHEt,

Ac-D-hArg(Et)$_2$-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Phe-NH_2,

Propionyl-D-hArg(Et)$_2$-Gly-Cys-Phe-D-Trp-Lys(iPr)-Thr-Cys-Thr-NH_2,

Ac-D-ß-Nal-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Gly-hArg(Et)$_2$-NH_2,

Ac-D-Lys(iPr)-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH_2,

Ac-D-hArg(CH_2CF_3)$_2$-D-hArg(CH_2CF_3)$_2$-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH_2,

Ac-D-hArg(CH_2CF_3)$_2$-D-hArg(CH_2CF_3)$_2$-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Phe-NH_2,

Ac-D-hArg(Et)$_2$-D-hArg(Et)$_2$-Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH_2,

Ac-Cys-Lys-Asn-4-Cl-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Ser-D-Cys-NH_2,

H-Bmp-Tyr-D-Trp-Lys-Val-Cys-Thr-NH_2,

H-Bmp-Tyr-D-Trp-Lys-Val-Cys-Phe-NH_2,

H-Bmp-Tyr-D-Trp-Lys-Val-Cys-p-Cl-Phe-NH_2,

H-Bmp-Tyr-D-Trp-Lys-Val-Cys-ß-Nal-NH_2,

H-D-ß-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH_2,

H-D-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH_2,

H-D-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-ß-Nal-NH_2,

H-pentafluoro-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH_2,

Ac-D-ß-Nal-Cys-pentafluoro-Phe-D-Trp-Lys-Val-Cys-Thr-NH_2,

H-D-ß-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-ß-Nal-NH_2,

H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-ß-Nal-NH_2,

H-D-ß-Nal-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH_2,

H-D-p-Cl-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH_2,

Ac-D-p-Cl-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH_2,

H-D-Phe-Cys-ß-Nal-D-Trp-Lys-Val-Cys-Thr-NH_2,

H-D-Phe-Cys-Tyr-D-Trp-Lys-Cys-Thr-NH_2,

cyclo(Pro-Phe-D-Trp-N-Me-Lys-Thr-Phe),

cyclo(Pro-Phe-D-Trp-N-Me-Lys-Thr-Phe),

cyclo(Pro-Phe-D-Trp-Lys-Thr-N-Me-Phe),

cyclo(N-Me-Ala-Tyr-D-Trp-Lys-Thr-Phe),

cyclo(Pro-Tyr-D-Trp-Lys-Thr-Phe),

cyclo(Pro-Phe-D-Trp-Lys-Thr-Phe),

cyclo(Pro-Phe-L-Trp-Lys-Thr-Phe)(SEQ ID NO:1),

cyclo(Pro-Phe-D-Trp(F)-Lys-Thr-Phe),

cyclo(Pro-Phe-Trp(F)-Lys-Thr-Phe) (SEQ ID NO:2),

cyclo(Pro-Phe-D-Trp-Lys-Ser-Phe),

cyclo(Pro-Phe-D-Trp-Lys-Thr-p-Cl-Phe),

cyclo(D-Ala-N-Me-D-Phe-D-Thr-D-Lys-Trp-D-Phe),

cyclo(D-Ala-N-Me-D-Phe-D-Val-Lys-D-Trp-D-Phe),

cyclo(D-Ala-N-Me-D-Phe-D-Thr-Lys-D-Trp-D-Phe),

cyclo(D-Abu-N-Me-D-Phe-D-Val-Lys-D-Trp-D-Tyr),

cyclo(Pro-Tyr-D-Trp-t-4-AchxAla-Thr-Phe),

cyclo(Pro-Phe-D-Trp-t-4-AchxAla-Thr-Phe),

cyclo(N-Me-Ala-Tyr-D-Trp-Lys-Val-Phe),

cyclo(N-Me-Ala-Tyr-D-Trp-t-4-AchxAla-Thr-Phe),

cyclo(Pro-Tyr-D-Trp-4-Amphe-Thr-Phe),

cyclo(Pro-Phe-D-Trp-4-Amphe-Thr-Phe),

cyclo(N-Me-Ala-Tyr-D-Trp-4-Amphe-Thr-Phe),

cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba),

cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba-Gaba),

cyclo(Asn-Phe-D-Trp-Lys-Thr-Phe),

cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-NH$(CH_2)_4$CO),

cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-ß-Ala),

cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-D-Glu)-OH,

cyclo(Phe-Phe-D-Trp-Lys-Thr-Phe),

cyclo(Phe-Phe-D-Trp-Lys-Thr-Phe-Gly),

cyclo(Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba),

cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gly),

cyclo(Asn-Phe-Phe-D-Trp(F)-Lys-Thr-Phe-Gaba),

cyclo(Asn-Phe-Phe-D-Trp(NO_2)-Lys-Thr-Phe-Gaba),

cyclo(Asn-Phe-Phe-Trp(Br)-Lys-Thr-Phe-Gaba) (SEQ ID NO:3),

cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Phe(I)-Gaba),

cyclo(Asn-Phe-Phe-D-Trp-Lys-Thr-Tyr(But)-Gaba),

cyclo(Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Pro-Cys)-OH,

cyclo(Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Pro-Cys)-OH,

cyclo(Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-Tpo-Cys)-OH,

cyclo(Bmp-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-MeLeu-Cys)-OH,

cyclo(Phe-Phe-D-Trp-Lys-Thr-Phe-Phe-Gaba),

cyclo(Phe-Phe-D-Trp-Lys-Thr-Phe-D-Phe-Gaba),

cyclo(Phe-Phe-D-Trp(5F)-Lys-Thr-Phe-Phe-Gaba),

cyclo(Asn-Phe-Phe-D-Trp-Lys(Ac)-Thr-Phe-NH-$(CH_2)_3$-CO),

cyclo(Lys-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba),

cyclo(Lys-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba),

cyclo(Orn-Phe-Phe-D-Trp-Lys-Thr-Phe-Gaba),

H-Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys-NH_2 ,

H-Cys-Phe-Phe-D-Trp-Lys-Ser-Phe-Cys-NH_2 ,

H-Cys-Phe-Tyr-D-Trp-Lys-Thr-Phe-Cys-NH_2 or

H-Cys-Phe-Tyr(I)-D-Trp-Lys-Thr-Phe-Cys-NH_2 .

24 (currently amended): ~~A~~ The method according to claim ~~1~~ 3 wherein the somatostatin agonist is



wherein

A^1 is a D- or L- isomer of Ala, Leu, Ile, Val, Nle, Thr, Ser, ß-Nal, ß-Pal, Trp, Phe, 2,4-dichloro-Phe, pentafluoro-Phe, p-X-Phe, or o-X-Phe, wherein X is CH_3, Cl, Br, F, OH, OCH_3 or NO_2;

A^2 is Ala, Leu, Ile, Val, Nle, Phe, ß-Nal, pyridyl-Ala, Trp, 2,4-dichloro-Phe, pentafluoro-Phe, o-X-Phe, or p-X-Phe, wherein X is CH_3, Cl, Br, F, OH, OCH_3 or NO_2;

A^3 is pyridyl-Ala, Trp, Phe, ß-Nal, 2,4-dichloro-Phe, pentafluoro-Phe, o-X-Phe, or p-X-Phe, wherein X is CH_3, Cl, Br, F, OH, OCH_3 or NO_2;

A^6 is Val, Ala, Leu, Ile, Nle, Thr, Abu, or Ser;

A^7 is Ala, Leu, Ile, Val, Nle, Phe, ß-Nal, pyridyl-Ala, Trp, 2,4-dichloro-Phe, pentafluoro-Phe, o-X-Phe, or p-X-Phe, wherein X is CH_3, Cl, Br, F, OH, OCH_3 or NO_2;

A^8 is a D- or L-isomer of Ala, Leu, Ile, Val, Nle, Thr, Ser, Phe, ß-Nal, pyridyl-Ala, Trp, 2,4-dichloro-Phe, pentafluoro-Phe, p-X-Phe, or o-X-Phe, wherein X is CH_3, Cl, Br, F, OH, OCH_3 or NO_2;

each R_1 and R_2, independently, is H, lower acyl or lower alkyl; and R_3 is OH or NH_2; provided that at least one of A^1 and A^8 and one of A^2 and A^7 must be an aromatic amino acid; and further provided that A^1, A^2, A^7 and A^8 cannot all be aromatic amino acids.

25 (currently amended): ~~A~~ The method according to claim 24 wherein the linear somatostatin agonist is
H-D-Phe-p-chloro-Phe-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH_2,
H-D-Phe-p-NO_2-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH_2,
H-D-Nal-p-chloro-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH_2,
H-D-Phe-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-NH_2 ,
H-D-Phe-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH_2,
H-D-Phe-p-chloro-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH_2 or
H-D-Phe-Ala-Tyr-D-Trp-Lys-Val-Ala-ß-D-Nal-NH_2.

26 (currently amended): ~~A~~ The method according to claim ~~1~~ 3 wherein the somatostatin agonist is







or



27 (canceled): A method according to claim 1 wherein said patient is obese.

28 (currently amended): ~~A~~ The method according to claim 3 wherein said patient is obese.

29 (canceled): A method according to claim 4 wherein said patient is obese.

30 (currently amended): ~~A~~ The method according to claim 7 wherein said patient is obese.

31 (canceled): A method according to claim 8 wherein said patient is obese.

32 (canceled): A method according to claim 11 wherein said patient is obese.